Standard BioTools Inc. Business Acquisition, Pro Forma Net Income (Loss)
Standard BioTools Inc. (LAB) reported Business Acquisition, Pro Forma Net Income (Loss) of -$168.65 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-03-11
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-12-31 was -$34.05M.
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-09-30 was -$26.94M.
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-06-30 was -$57.67M.
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-03-31 was -$50.02M.
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for fiscal 2024 was -$168.65M.
- Standard BioTools Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$164.28M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$60.98M derived: sum of 2 quarters · filed 2025-03-11 | -$118.66M derived: sum of 3 quarters · filed 2025-03-11 | -$168.65M 10-K · filed 2025-03-11 |
| 2024-09-30 | -$26.94M 10-Q · filed 2024-11-06 | -$84.61M derived: sum of 2 quarters · filed 2024-11-06 | -$134.61M 10-Q · filed 2024-11-06 | -$189.91M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | -$57.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$107.69M 10-Q · filed 2024-08-06 | -$162.97M derived: sum of 3 quarters · filed 2025-03-11 | -$204.18M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | -$50.02M 10-Q · filed 2024-05-09 | -$105.30M derived: sum of 2 quarters · filed 2025-03-11 | -$146.50M derived: sum of 3 quarters · filed 2025-03-11 | -$186.06M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | -$55.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$96.48M derived: sum of 2 quarters · filed 2025-03-11 | -$136.04M derived: sum of 3 quarters · filed 2025-03-11 | -$164.28M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$41.20M 10-Q · filed 2024-11-06 | -$80.76M derived: sum of 2 quarters · filed 2024-11-06 | -$109.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$39.56M 10-Q · filed 2024-08-06 | -$67.80M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$45.05M 10-Q · filed 2024-05-09 | |||
| 2014-06-30 | -$11.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | -$30.52M 10-Q · filed 2014-08-04 | ||
| 2014-03-31 | -$18.99M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |